Abstract
BackgroundTo determine the potential of the combination of DCE-MRI imaging method with DWI and serum CA125 and CA199 levels in the evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients.MethodsSixty-five breast cancer patients who received neoadjuvant chemotherapy in our hospital from April 2016 to April 2017 were selected as research subjects. The patients received 4 courses of neoadjuvant chemotherapy. Lesions were monitored using DCE-MRI and DWI, while ELISA was used to measure the serum expression levels of the tumour markers CA125 and CA199. The patients were divided into the remission group and ineffective group based on pathological diagnosis.ResultsThere were significant differences in Kep, Ktrans, ADCmin, ADCmean, tumour volume, and serum levels of CA125 and CA199 in patients in the remission group, before and after neoadjuvant chemotherapy, and there were significant differences in post-chemotherapy values of these indexes between the remission group and the ineffective group (p < 0.01).ConclusionCombination of DCE-MRI diagnostic imaging with DWI can directly reflect the lesions in breast cancer patients after neoadjuvant chemotherapy. Serum levels of CA125 and CA199 levels are useful for evaluation of the impact of neoadjuvant chemotherapy on breast cancer patients, including risk of cancer cell metastasis and changes in some small lesions.
Highlights
Breast cancer is one of the common gynecological diseases with high morbidity and mortality, and it is a serious threat to the health of women [1,2,3]
This study showed that the serum levels of CA125 and CA199 in patients in the remission group were significantly reduced during neoadjuvant chemotherapy, and there were significant differences in the serum CA125 and CA199 levels after neoadjuvant chemotherapy between the remission group and the ineffective group
These results indicate that the serum expression levels of CA125 and CA199 can effectively be used to determine the therapeutic effect of neoadjuvant chemotherapy
Summary
Breast cancer is one of the common gynecological diseases with high morbidity and mortality, and it is a serious threat to the health of women [1,2,3]. Neoadjuvant chemotherapy refers to systemic chemotherapy before surgical resection or local radiotherapy on the lesions. It reduces the risk of cancer cell metastasis to a certain. Zhang et al World Journal of Surgical Oncology (2021) 19:284 evaluated using the diagnostic imaging method of DCEMRI and DWI in combination with serum levels of CA125 and CA199. To determine the potential of the combination of DCE-MRI imaging method with DWI and serum CA125 and CA199 levels in the evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
